Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00303719 · ClinicalTrials.gov registry record · Phase 2
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- Phase 2
- Development phase
- 342
- Enrollment target
NCT00303719 is a Phase 2 study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 342 participants.
The verdict
NCT00303719, a Phase 2 study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 342 participants
- Enrollment target
Study Summary
RATIONALE: A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and radiation therapy, or that have become cancer. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclophosphamide and fludarabine together with total-body irradiation followed by cyclosporine and mycophenolate mofetil before the transplant may stop this from happening. PURPOSE: This clinical trial is studying how well giving combination chemotherapy together with radiation therapy followed by cyclosporine and mycophenolate mofetil works in treating patients who are undergoing a donor stem cell transplant for hematologic cancer, metastatic breast cancer, or kidney cancer.
Interventions
- DRUG fludarabine
- DRUG cyclophosphamide
- DRUG cyclosporine
- BIOLOGICAL anti-thymocyte globulin
- DRUG mycophenolate mofetil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 342 participants |
| Start Date | 2002-03-26 |
| Est. Completion | 2019-05-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00303719
The ClinicalTrials.gov registry entry for NCT00303719 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 342 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which fludarabine is the first listed.
NCT00303719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00303719 about?
NCT00303719 is a clinical study titled "Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy". RATIONALE: A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and radiation therapy, or that have become cancer. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclophosph...
What is the current status of trial NCT00303719?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 342 participants. The study started on 2002-03-26. Estimated completion is 2019-05-08.
What interventions are being tested in trial NCT00303719?
The interventions under investigation include: fludarabine (DRUG), cyclophosphamide (DRUG), cyclosporine (DRUG), anti-thymocyte globulin (BIOLOGICAL), mycophenolate mofetil (DRUG).
Who is sponsoring clinical trial NCT00303719?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.